Equities

GlucoTrack Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
GCTK:NAQ

GlucoTrack Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.63
  • Today's Change-0.16 / -8.94%
  • Shares traded10.00
  • 1 Year change-94.88%
  • Beta0.3046
Data delayed at least 15 minutes, as of Feb 12 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.

  • Revenue in USD (TTM)0.00
  • Net income in USD-25.85m
  • Incorporated2010
  • Employees11.00
  • Location
    GlucoTrack Inc301 Rt 17 North, Suite 800RUTHERFORD 07070United StatesUSA
  • Phone+1 (9728) 675-7878
  • Fax+1 (302) 655-5049
  • Websitehttps://glucotrack.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Herborium Group Inc340.33k-318.65k1.09m2.00------3.21-0.3492-0.34920.3672-1.162.323.8925.94---216.97-490.56----58.3156.36-93.63-186.810.0331-39.14----19.45-18.15120.44------
Halberd Corp281.24k25.34k1.13m3.000.6897--44.614.020.00230.00230.0018-0.00020.14490.03032.52--1.31--4.58--50.00--9.01--0.26611.351.02--271.52---60.11------
Aditxt Inc5.95k-42.24m1.23m26.00------206.02-13,234.74-13,234.740.3444-151.860.00031.540.0304228.85-207.03-148.78---279.11-1,134.96---724,419.70-8,283.150.02-12.48-----79.23---23.40------
Pharmagreen Biotech Inc3.01k-226.26k1.26m0.00----2.28418.91-0.0003-0.00030.00-0.00350.02860.20260.0669---214.92-709.50----44.85---7,518.27-147,637.600.0375------13.67---76.59------
International Stem Cell Corp9.39m-149.00k1.32m32.00----8.200.1406-0.0187-0.01871.170.06551.802.6611.08293,468.80-1.13-16.11-10.84-52.8857.8659.53-0.6283-10.910.46040.62580.8632--16.64-0.8308-59.54---19.12--
Ensysce Biosciences Inc4.49m-10.97m1.46m7.00--1.09--0.3259-6.36-6.362.320.37830.7144--5.02641,138.60-174.67-48.70-270.43-62.66-----244.49-501.34---457.150.3071--133.58--24.83------
Purminds Enterprises Inc0.00-77.46k1.48m0.00--0.0409-----0.1832-0.18320.000.76460.00-------26.19-620.48-66.38-------------6.290.00-------13.29------
GlucoTrack Inc0.00-25.85m1.48m11.00--0.5329-----1,225.32-1,225.320.003.060.00----0.00-567.22-147.48---192.87-----------3.510.5422-------218.40--34.73--
Virax Biolabs Group Ltd2.99k-5.64m1.55m19.00--0.2576--519.14-1.25-1.250.00070.81180.00040.53821.94157.37-74.60-111.16-77.64-133.38-1,515.05-4.50-189,095.00-7,009.4211.21-92.320.0959---95.95-42.409.98------
Carisma Therapeutics Inc52.63m8.04m1.61m46.000.2047--0.16870.03060.18810.18811.26-0.02082.17----1,144,174.0033.09-26.5851.48-30.35----15.28-169.12--------31.59--30.39---1.99--
Clearmind Medicine Inc0.00-3.86m1.63m----0.1445-----30.64-30.640.007.540.00-------57.83-128.70-178.71-360.04------------0.5987------26.60------
Agentix Corp0.00-655.59k1.68m-----------0.0164-0.01640.00-0.08530.00-------746.86-----------------7.07--------3.09------
Galera Therapeutics Inc0.00-8.99m1.80m3.00---------0.1302-0.13020.00-1.940.00----0.00-129.27-96.94-145.04-116.42------------34.30------67.91------
Exousia Pro Inc0.00-854.02k1.83m0.00---------0.0642-0.06420.00-0.03180.00-------1,313,877.00-----------------1,816.06---------248.31------
CDT Equity Inc0.00-20.70m1.92m6.00--0.3103-----473.79-473.790.003.350.00----0.00-358.56-----------------16.000.2881-------3,227.48------
Data as of Feb 12 2026. Currency figures normalised to GlucoTrack Inc's reporting currency: US Dollar USD

Institutional shareholders

1.70%Per cent of shares held by top holders
HolderShares% Held
Abante Asesores Gesti�n SGIIC SAas of 31 Dec 20259.06k1.00%
Alerus Financial, NA (Private Banking)as of 30 Sep 20255.00k0.55%
Tower Research Capital LLCas of 30 Sep 2025806.000.09%
Morgan Stanley & Co. LLCas of 30 Sep 2025400.000.04%
UBS Securities LLCas of 31 Dec 2025119.000.01%
Newbridge Financial Services Group, Inc.as of 31 Dec 202534.000.00%
SBI Securities Co., Ltd.as of 31 Dec 20259.000.00%
Bank of America, NA (Private Banking)as of 30 Sep 20257.000.00%
Osaic Advisory Services LLCas of 30 Sep 20251.000.00%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 20251.000.00%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.